Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

The NASH drug dash

Nature Reviews Drug Discovery volume 14, pages 447–448 (2015)Cite this article

Subjects

Intercept Pharmaceuticals has announced plans for the first ever pivotal trial in non-alcoholic steatohepatitis (NASH), setting a high bar for a growing pipeline of drugs against the liver disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Kelly Rae Chi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chi, K. The NASH drug dash. Nat Rev Drug Discov 14, 447–448 (2015). https://doi.org/10.1038/nrd4667

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4667

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research